Research location

Shirley

New York, United States

Published trials26

Site observations26

Linked trials published26

Page1 / 1

Research activity in Shirley

New York, United States

CureCurrent currently publishes aggregate city-level research activity for this location: 26 trials and 26 site observations.

The map is centered on registry-derived city coordinates. Circle size reflects published trial activity.

Below are current trials with one or more ClinicalTrials.gov site observations in this city. Results are paginated 50 per page, with recruiting studies shown first.

Trials with sites in Shirley

26 linked trials · page 1 of 1

BGB-43395 Plus Letrozole Versus CDK4/6i Plus Letrozole for Patients With Advanced or Metastatic HR+/HER2- Breast Cancer Who Have Not Received Prior Treatment for Advanced or Metastatic DiseaseNCT07492641 · 2026-05-22 · 1 site observation

RO7771950 Versus Tucatinib in Combination With Trastuzumab and Capecitabine in People With Locally Advanced or Metastatic Breast Cancer That is Human Epidermal Growth Factor Receptor 2 (HER2)-PositiveNCT07413939 · 2026-05-21 · 1 site observation

A Study of Imlunestrant (LY3484356) in Premenopausal Women With Estrogen Receptor-Positive (ER+) Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Early Breast CancerNCT07287098 · 2026-05-13 · 1 site observation

A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast CancerNCT06790693 · 2025-04-09 · 1 site observation

Study to Evaluate Adverse Events and Efficacy of Intravenous (IV) Telisotuzumab Adizutecan in Combination With a PD-1 Immune Checkpoint Inhibitor in Adult Participants With Advanced or Metastatic Non-Squamous NSCLC With No Prior Treatment for Advanced Disease, and No Actionable Genomic AlterationsNCT06772623 · 2025-03-06 · 1 site observation

Pan-tumor MRD StudyNCT06605404 · 2025-01-08 · 1 site observation

A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)NCT06667076 · 2024-12-16 · 1 site observation

Saruparib (AZD5305) Plus Camizestrant or Plus Endocrine Therapy, Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast CancerNCT06380751 · 2024-08-01 · 1 site observation

LUNAR-2: TTFields With Pembrolizumab + Platinum-based Chemotherapy for Metastatic NSCLCNCT06216301 · 2024-07-31 · 1 site observation

Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has SpreadNCT06324357 · 2024-06-28 · 1 site observation

Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)NCT05633654 · 2022-12-12 · 1 site observation

A Phase 1/2a Study of DB-1303/BNT323 in Advanced/Metastatic Solid TumorsNCT05150691 · 2022-01-31 · 1 site observation

A Study of Sigvotatug Vedotin in Advanced Solid TumorsNCT04389632 · 2020-06-08 · 1 site observation

A Study Comparing Tarlatamab, Durvalumab, Carboplatin, and Etoposide Versus Durvalumab, Carboplatin, and Etoposide in First-line Extensive Stage Small-Cell Lung Cancer (ES-SCLC)NCT07005128 · 2025-08-18 · 1 site observation

ACTIVE_NOT_RECRUITING

A Study to Compare ABP 234 and Keytruda® (Pembrolizumab) in Participants With Advanced or Metastatic Non-squamous Non-Small Cell Lung CancerNCT06311721 · 2024-09-09 · 1 site observation

ACTIVE_NOT_RECRUITING

A Study to Investigate the Efficacy of Durvalumab Plus Tremelimumab in Combination With Chemotherapy Compared With Pembrolizumab in Combination With Chemotherapy in Metastatic NSCLC Patients With Non-squamous Histology Who Have Mutations and/or Co-mutations in STK11, KEAP1, or KRASNCT06008093 · 2024-04-04 · 1 site observation

ACTIVE_NOT_RECRUITING

Study of Non-Small Cell Lung Cancer Patients in the US Receiving Standard-of-Care and Initiating an Approved Therapy With Risk of Pneumonitis/ILDNCT06192004 · 2024-01-05 · 1 site observation

Observational Lung Trial to Collect Tissue to Train and Validate a Live Tumor Diagnostic Platform (ELEPHAS-01)NCT05478538 · 2023-01-31 · 1 site observation

ACTIVE_NOT_RECRUITING

Study of INCB123667 in Subjects With Advanced Solid TumorsNCT05238922 · 2022-07-05 · 1 site observation

ACTIVE_NOT_RECRUITING

ARX788 in HER2-positive, Metastatic Breast Cancer Subjects (ACE-Breast-03)NCT04829604 · 2021-10-26 · 1 site observation

ACTIVE_NOT_RECRUITING

Phase III Study to Assess AZD9833+ CDK4/6 Inhibitor in HR+/HER2-MBC With Detectable ESR1m Before Progression (SERENA-6)NCT04964934 · 2021-06-30 · 1 site observation

ACTIVE_NOT_RECRUITING

Trastuzumab Deruxtecan (T-DXd) With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive Metastatic Breast Cancer (DESTINY-Breast09)NCT04784715 · 2021-04-26 · 1 site observation

ACTIVE_NOT_RECRUITING

Study of the Safety and Efficacy of APX3330 in Diabetic RetinopathyNCT04692688 · 2021-04-08 · 1 site observation

Fenofibrate for Prevention of DR WorseningNCT04661358 · 2021-03-05 · 1 site observation

ACTIVE_NOT_RECRUITING

Study of a High-Dose Aflibercept in Participants With Diabetic Eye DiseaseNCT04429503 · 2020-06-29 · 1 site observation

A Study of Neoadjuvant/Adjuvant Durvalumab for the Treatment of Patients With Resectable Non-small Cell Lung CancerNCT03800134 · 2018-12-06 · 1 site observation

ACTIVE_NOT_RECRUITING

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.